View Item 

Show simple item record

Accommodation in ABO‐incompatible organ transplants
dc.contributor.authorGarcia de Mattos Barbosa, Mayara
dc.contributor.authorCascalho, Marilia
dc.contributor.authorPlatt, Jeffrey L.
dc.date.accessioned2018-07-13T15:46:47Z
dc.date.available2019-07-01T14:52:17Zen
dc.date.issued2018-05
dc.identifier.citationGarcia de Mattos Barbosa, Mayara; Cascalho, Marilia; Platt, Jeffrey L. (2018). "Accommodation in ABO‐incompatible organ transplants." Xenotransplantation (3): n/a-n/a.
dc.identifier.issn0908-665X
dc.identifier.issn1399-3089
dc.identifier.urihttps://hdl.handle.net/2027.42/144607
dc.description.abstractAccommodation refers to a condition in which a transplant (or any tissue) appears to resist immune‐mediated injury and loss of function. Accommodation was discovered and has been explored most thoroughly in ABO‐incompatible kidney transplantation. In this setting, kidney transplants bearing blood group A or B antigens often are found to function normally in recipients who lack and hence produce antibodies directed against the corresponding antigens. Whether accommodation is owed to changes in anti‐blood group antibodies, changes in antigen or a change in the response of the transplant to antibody binding are critically reviewed and a new working model that allows for the kinetics of development of accommodation is put forth. Regardless of how accommodation develops, observations on the fate of ABO‐incompatible transplants offer lessons applicable more broadly in transplantation and in other fields.
dc.publisherBlackwell Scientific Publications
dc.publisherWiley Periodicals, Inc.
dc.subject.otherblood type
dc.subject.otherkidney transplant
dc.subject.otherrejection
dc.subject.otherblood group
dc.subject.otheraccommodation
dc.subject.otherABO‐incompatible transplant
dc.titleAccommodation in ABO‐incompatible organ transplants
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNatural Resources and Environment
dc.subject.hlbtoplevelScience
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144607/1/xen12418.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144607/2/xen12418_am.pdf
dc.identifier.doi10.1111/xen.12418
dc.identifier.sourceXenotransplantation
dc.identifier.citedreferenceRydberg L, Samuelsson BE. Presence of glycosyltransferase inhibitors in the sera of patients with long‐term surviving ABO incompatible (A2 to O) kidney grafts. Transfus Med. 1991; 1: 177 ‐ 182.
dc.identifier.citedreferenceEverett ML, Lin SS, Worrell SS, Platt J, Parker W. The footprint of antibody bound to pig cells: evidence of complex surface topology. Biochem Biophys Res Comm. 2003; 301: 751 ‐ 757.
dc.identifier.citedreferenceSaadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement‐mediated regulation of tissue factor activity in endothelium. J Exp Med. 1995; 182: 1807 ‐ 1814.
dc.identifier.citedreferenceParker W, Lin SS, Platt JL. Antigen expression in xenotransplantation: how low must it go? Transplantation. 2001; 71: 313 ‐ 319.
dc.identifier.citedreferenceFischel RJ, Bolman RM, Platt JL, Najarian JS, Bach FH, Matas AJ. Removal of IgM anti‐endothelial antibodies results in prolonged cardiac xenograft survival. Transpl Proc. 1990; 22: 1077 ‐ 1078.
dc.identifier.citedreferenceLynch RJ, Platt JL. Escaping from Rejection. Transplantation. 2009; 88: 1233 ‐ 1266.
dc.identifier.citedreferenceCascalho MI, Chen BJ, Kain M, Platt JL. The paradoxical functions of B cells and antibodies in transplantation. J Immunol. 2013; 190: 875 ‐ 879.
dc.identifier.citedreferenceDijke EI, Platt JL, Blair P, et al. B cells in transplantation. J Heart Lung Transplant. 2016; 35: 704 ‐ 710.
dc.identifier.citedreferenceBach FH, Ferran C, Hechenleitner P, et al. Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment. Nat Med. 1997; 3: 196 ‐ 204.
dc.identifier.citedreferenceKoch CA, Kanazawa A, Nishitai R, et al. Intrinsic resistance of hepatocytes to complement‐mediated injury. J Immunol. 2005; 174: 7302 ‐ 7309.
dc.identifier.citedreferenceCourtney AE, McNamee PT, Middleton D, Heggarty S, Patterson CC, Maxwell AP. Association of functional heme oxygenase‐1 gene promoter polymorphism with renal transplantation outcomes. Am J Transplant. 2007; 7: 908 ‐ 913.
dc.identifier.citedreferenceCourtney AE, Maxwell AP. Heme oxygenase 1: does it have a role in renal cytoprotection? Am J Kidney Dis. 2008; 51: 678 ‐ 690.
dc.identifier.citedreferencePlatt JL, Kaufman CL, Garcia DE, Mattos Barbosa M, Cascalho M. Accommodation and related conditions in vascularized composite allografts. Curr Opin Organ Transplant. 2017; 22: 470 ‐ 476.
dc.identifier.citedreferenceSaadi S, Wrenshall LE, Platt JL. Regional manifestations and control of the immune system. FASEB J. 2002; 16: 849 ‐ 856.
dc.identifier.citedreferenceLynch RJ, Silva IA, Chen BJ, Punch JD, Cascalho M, Platt JL. Cryptic B cell response to renal transplantation. Am J Transplant. 2013; 13: 1713 ‐ 1723.
dc.identifier.citedreferencePlatt JL. C4d and the fate of organ allografts. J Am Soc Nephrol. 2002; 13: 2417 ‐ 2419.
dc.identifier.citedreferenceIhrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune system‐blood vessel interactions. Immunol Today. 1993; 14: 500 ‐ 505.
dc.identifier.citedreferenceKoch CA, Khalpey ZI, Platt JL. Accommodation: preventing injury in transplantation and disease. J Immunol. 2004; 172: 5143 ‐ 5148.
dc.identifier.citedreferencePlatt JL, Zhou X, Lefferts AR, Cascalho M. Cell Fusion in the war on cancer: a perspective on the inception of malignancy. Int J Mol Sci. 2016; 17: pii: E1118.
dc.identifier.citedreferenceCascalho M, Platt JL. Harnessing B cells in immunotherapy. Immunotherapy. 2016; 8: 237 ‐ 239.
dc.identifier.citedreferenceCarpenter CB, D’Apice AJ, Abbas AK. The role of antibodies in the rejection and enhancement of organ allografts. Adv Immunol. 1976; 22: 1 ‐ 65.
dc.identifier.citedreferenceCooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donor‐specific antibodies are due to acute rejection episodes. Transplantation. 2011; 91: 1103 ‐ 1109.
dc.identifier.citedreferenceCollins BH, Cotterell AH, McCurry KR, et al. Cardiac xenografts between primate species provide evidence for the importance of the a‐galactosyl determinant in hyperacute rejection. J Immunol. 1995; 154: 5500 ‐ 5510.
dc.identifier.citedreferenceDauber LG, Reed LJ. ABO antibodies. I. Methods for quantification of ABO hemolysins and soluble blood group substances A and B (interim report). Rep No 818. Rep US Army Med Res Lab. 1969; 10: 1 ‐ 21.
dc.identifier.citedreferenceHume DM, Merrill JP, Miller BF, Thorn GW. Experiences with renal homotransplantation in the human: report of nine cases. J Clin Invest. 1955; 34: 327 ‐ 382.
dc.identifier.citedreferenceMurray JE, Harrison JH. Surgical management of fifty patients with kidney transplants including eighteen pairs of twins. Am J Surg. 1963; 105: 205 ‐ 218.
dc.identifier.citedreferenceHamburger J, Crosnier J, Dormont J. Experience with 45 renal homotransplantations in man. Lancet. 1965; 1: 985 ‐ 992.
dc.identifier.citedreferenceMoore FD, Burch GE, Harken DE, Swan HJ, Murray JE, Lillihei CW. Cardiac and other organ transplantation. In the setting of transplant science as a national effort. JAMA. 1968; 206: 2489 ‐ 2500.
dc.identifier.citedreferenceMurnaghan GF, Jeremy D, Tracy GD, Farnsworth RH, McCredie KB. Successful human cadaveric renal homograft with major blood‐group incompatibility. Lancet. 1967; 2: 852 ‐ 854.
dc.identifier.citedreferenceStarzl TE, Marchioro TL, Hermann G, Brittain RS, Waddell WR. Renal homografts in patients with major donor‐recipient blood group incompatibilities. Surgical Forum. 1963; XIV: 214 ‐ 216.
dc.identifier.citedreferenceStarzl TE, Marchioro TL, Holmes JH, et al. Renal homografts in patients with major donor‐recipient blood group incompatibilities. Surgery. 1964; 55: 195 ‐ 200.
dc.identifier.citedreferenceStarzl TE, Marchioro TL, Holmes JH, Waddell WR. The incidence, cause, and significance of immediate and delayed oliguria or anuria after human renal transplantation. Surg Gynecol Obst. 1964; 118: 819 ‐ 827.
dc.identifier.citedreferenceDunea G, Nakamoto S, Straffon RA, et al. Renal homotransplantation in 24 patients. Br Med J. 1965; 1: 7 ‐ 13.
dc.identifier.citedreferenceGleason RE, Murray JE. Report from kidney transplant registry: analysis of variables in the function of human kidney transplants. Transplantation. 1967; 5: 343 ‐ 359.
dc.identifier.citedreferenceRydberg L. ABO‐incompatibility in solid organ transplantation. Transfus Med. 2001; 11: 325 ‐ 342.
dc.identifier.citedreferenceToma H, Tanabe K, Tokumoto T. Long‐term outcome of ABO‐incompatible renal transplantation. Urol Clin North Am. 2001; 28: 769 ‐ 780.
dc.identifier.citedreferenceMontgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO‐incompatible kidney transplantation in the United States. Transplantation. 2012; 93: 603 ‐ 609.
dc.identifier.citedreferenceCutbush M, Mollison PL. Relation between characteristics of blood‐group antibodies in vitro and associated patterns of red‐cell destruction in vivo. Br J Haematol. 1958; 4: 115 ‐ 137.
dc.identifier.citedreferenceMollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. London, UK: Blackwell Scientific Publications; 1993.
dc.identifier.citedreferenceBorsos T, Rapp HJ. Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol. 1965; 95: 559 ‐ 566.
dc.identifier.citedreferenceHumphrey JH. Haemolytic efficiency of rabbit IgG anti‐Forssman antibody and its augmentation by anti‐rabbit IgG. Nature. 1967; 216: 1295 ‐ 1296.
dc.identifier.citedreferenceSchreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement‐fixing sites and effects of their interaction with serum. J Clin Invest. 1972; 51: 583 ‐ 589.
dc.identifier.citedreferencePlatt JL, Wrenshall LE, Johnson GB, Cascalho M. Heparan sulfate proteoglycan metabolism and the fate of grafted tissues. Adv Exp Med Biol. 2015; 865: 123 ‐ 140.
dc.identifier.citedreferenceKoski CL, Ramm LE, Hammer CH, Mayer MM, Shin ML. Cytolysis of nucleated cells by complement: cell death displays multi‐hit characteristics. Proc Nat Acad Sci. 1983; 80: 3816 ‐ 3820.
dc.identifier.citedreferenceMorgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987; 138: 246 ‐ 253.
dc.identifier.citedreferenceShin ML, Carney DF. Cytotoxic action and other metabolic consequences of terminal complement proteins. Prog Allergy. 1988; 40: 44 ‐ 81.
dc.identifier.citedreferenceMorgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non‐lethal effects. Biochem J. 1989; 264: 1 ‐ 14.
dc.identifier.citedreferencePlatt JL, Vercellotti GM, Lindman BJ, Oegema Jr TR, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med. 1990; 171: 1363 ‐ 1368.
dc.identifier.citedreferencePlatt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine‐to‐primate model. Transplantation. 1991; 52: 214 ‐ 220.
dc.identifier.citedreferenceVercellotti GM, Platt JL, Bach FH, Dalmasso AP. Enhanced neutrophil adhesion to xenogeneic endothelium via C3bi. J Immunol. 1991; 146: 730 ‐ 734.
dc.identifier.citedreferenceSaadi S, Platt JL. Transient perturbation of endothelial integrity induced by natural antibodies and complement. J Exp Med. 1995; 181: 21 ‐ 31.
dc.identifier.citedreferencePlatt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today. 1990; 11: 450 ‐ 456.
dc.identifier.citedreferenceWilbrandt R, Tung KSK, Deodhar SD, Nakamoto S, Kolff WJ. ABO blood group incompatibility in human renal homotransplantation. Am J Clin Pathol. 1969; 51: 15 ‐ 23.
dc.identifier.citedreferenceCascalho M, Platt JL. The immunological barrier to xenotransplantation. Immunity. 2001; 14: 437 ‐ 446.
dc.identifier.citedreferenceSaadi S, Takahashi T, Holzknecht RA, Platt JL. Pathways to acute humoral rejection. Am J Pathol. 2004; 164: 1073 ‐ 1080.
dc.identifier.citedreferenceCascalho M, Platt JL. Basic mechanisms of humoral rejection. Pediatr Transplant. 2005; 9: 9 ‐ 16.
dc.identifier.citedreferenceBrunn GJ, Saadi S, Platt JL. Differential regulation of endothelial cell activation by complement and interleukin 1 alpha. Circ Res. 2006; 98: 793 ‐ 800.
dc.identifier.citedreferencePlatt JL, Cascalho M. Donor specific antibodies after transplantation. Pediatr Transplant. 2011; 15: 686 ‐ 690.
dc.identifier.citedreferenceAtkinson JP, Frank MM. Studies on the in vivo effects of antibody. J Clin Invest. 1974; 54: 339 ‐ 348.
dc.identifier.citedreferenceCosio FG, Qiu W, Henry ML, et al. Factors related to the donor organ are major determinants of renal allograft function and survival. Transplantation. 1996; 62: 1571 ‐ 1576.
dc.identifier.citedreferenceLouvar DW, Li N, Snyder J, Peng Y, Kasiske BL, Israni AK. “Nature versus nurture” study of deceased‐donor pairs in kidney transplantation. J Am Soc Nephrol. 2009; 20: 1351 ‐ 1358.
dc.identifier.citedreferenceTraynor C, O’Kelly P, Denton M, Magee C, Conlon PJ. Concordance of outcomes of pairs of kidneys transplanted into different recipients. Transpl Int. 2012; 25: 918 ‐ 924.
dc.identifier.citedreferenceRydberg L, Breimer ME, Brynger H, Samuelsson BE. ABO‐incompatible kidney transplantation (A2 to O). Qualitative and semiquantitative studies of the humoral immune response against different blood group A antigens. Transplantation. 1990; 49: 954 ‐ 960.
dc.identifier.citedreferenceNelson PW, Helling TS, Shield CF, Beck M, Bryan CF. Current experience with renal transplantation across the ABO barrier. Am J Surg. 1992; 164: 541 ‐ 544; discussion 544‐545.
dc.identifier.citedreferenceShimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti‐A/B antibody titers in results of ABO‐incompatible kidney transplantation. Transplantation. 2000; 70: 1331 ‐ 1335.
dc.identifier.citedreferenceGloor JM, Lager DJ, Moore SB, et al. ABO‐incompatible kidney transplantation using both A2 and non‐A2 living donors. Transplantation. 2003; 75: 971 ‐ 977.
dc.identifier.citedreferenceBryan CF, Cherikh WS, Sesok‐Pizzini DA. A2 /A2 B to B renal transplantation: past, present, and future directions. Am J Transplant. 2016; 16: 11 ‐ 20.
dc.identifier.citedreferenceBrynger H, Rydberg L, Samuelsson BE, Sandberg L. Experience with 14 renal transplants with kidneys from blood group A (subgroup A 2 ) to O recipients. Transpl Proc. 1984; 16: 1175.
dc.identifier.citedreferenceBreimer ME, Samuelsson BE. The specific distribution of glycolipid‐based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation. 1986; 42: 88 ‐ 91.
dc.identifier.citedreferenceNelson PW, Helling TS, Pierce GE, et al. Successful transplantation of blood group A2 kidneys into non‐A recipients. Transplantation. 1988; 45: 316 ‐ 319.
dc.identifier.citedreferenceRydberg L, Breimer ME, Samuelsson BE, Brynger H. Blood group ABO‐incompatible (A2 to O) kidney transplantation in human subjects: a clinical, serologic, and biochemical approach. Transplant Proc. 1987; 19: 4528 ‐ 4537.
dc.identifier.citedreferenceWelsh KI, van Dam M, Koffman CG, et al. Transplantation of blood group A2 kidneys into O or B recipients: the effect of pretransplant anti‐A titers on graft survival. Transplant Proc. 1987; 19: 4565 ‐ 4567.
dc.identifier.citedreferenceChopek MW, Simmons RL, Platt JL. ABO‐incompatible renal transplantation: initial immunopathologic evaluation. Transpl Proc. 1987; 19: 4553 ‐ 4557.
dc.identifier.citedreferenceAlexandre GP, de Bruyere M, Squifflet JP, Moriau M, Latinne D, Pirson Y. Human ABO‐incompatible living donor renal homografts. Neth J Med. 1985; 28: 231 ‐ 234.
dc.identifier.citedreferenceAlexandre GPJ, Squifflet JP, de Bruyere M, et al. Present experiences in a series of 26 ABO‐incompatible living donor renal allografts. Transpl Proc. 1987; 19: 4538 ‐ 4542.
dc.identifier.citedreferenceBannett AD, McAlack RF, Raja R, Baquero A, Morris M. Experiences with known ABO‐mismatched renal transplants. Transpl Proc. 1987; 19: 4543 ‐ 4546.
dc.identifier.citedreferenceBreimer ME, Brynger H, le Pendu J, et al. Blood group ABO‐incompatible kidney transplantation biochemical and immunochemical studies of blood group A glycolipid antigens in human kidney and characterization of the antibody response (antigen specificity and antibody class) in O recipients receiving A2 grafts. Transplant Proc. 1987; 19: 226 ‐ 230.
dc.identifier.citedreferencePark W, Grande JP, Ninova D, et al. Accommodation in ABO‐incompatible kidney allografts, a novel mechanism of self‐protection against antibody‐mediated injury. Am J Transplant. 2003; 3: 952 ‐ 960.
dc.identifier.citedreferenceFan X, Lang H, Brown J, et al. Induction of human blood group A‐antigen expression on mouse cells using lentiviral gene transduction. Hum Gene Ther. 2010; 21: 877 ‐ 890.
dc.identifier.citedreferenceTasaki M, Saito K, Nakagawa Y, et al. Acquired Downregulation of Donor‐Specific Antibody Production After ABO‐Incompatible Kidney Transplantation. Am J Transplant. 2017; 17: 115 ‐ 128.
dc.identifier.citedreferenceHaas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO‐ and HLA‐incompatible renal allografts: correlation with histologic findings. Am J Transplant. 2006; 6: 1829 ‐ 1840.
dc.identifier.citedreferenceDorje C, Mjoen G, Strom EH, et al. One‐year protocol biopsies from ABO‐incompatible renal allografts compared with a matched cohort of ABO‐compatible allografts. Clin Transplant. 2015; 29: 268 ‐ 276.
dc.identifier.citedreferenceIshihara H, Ishida H, Unagami K, et al. Evaluation of microvascular inflammation in ABO‐incompatible kidney transplantation. Transplantation. 2017; 101: 1423 ‐ 1432.
dc.identifier.citedreferenceShimmura H, Tanabe K, Ishida H, et al. Lack of correlation between results of ABO‐incompatible living kidney transplantation and anti‐ABO blood type antibody titers under our current immunosuppression. Transplantation. 2005; 80: 985 ‐ 988.
dc.identifier.citedreferenceIshida H, Kondo T, Shimizu T, Nozaki T, Tanabe K. Postoperative rebound of antiblood type antibodies and antibody‐mediated rejection after ABO‐incompatible living‐related kidney transplantation. Transpl Int. 2015; 28: 286 ‐ 296.
dc.identifier.citedreferenceCooper DKC, Human PA, Lexer G, et al. Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J Heart Transplant. 1988; 7: 238 ‐ 246.
dc.identifier.citedreferencePlatt JL, Turman MA, Noreen HJ, Fischel RJ, Bolman RM, Bach FH. An ELISA assay for xenoreactive natural antibodies. Transplantation. 1990; 49: 1000 ‐ 1001.
dc.identifier.citedreferenceBannett AD, McAlack RF, Morris M, Chopek M, Platt JL. ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplant. Transpl Proc. 1989; 21: 783 ‐ 785.
dc.identifier.citedreferencePaul LC, van Es LA, de la Reviere GB, Eernisse G, de Graeff J. Blood group B antigen on renal endothelium as the target for rejection in an ABO‐incompatible recipient. Transplantation. 1978; 26: 268 ‐ 271.
dc.identifier.citedreferenceParker W, Holzknecht ZE, Song A, et al. Fate of antigen in xenotransplantation: implications for acute vascular rejection and accommodation. Am J Pathol. 1998; 152: 829 ‐ 839.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
xen12418.pdf
Size:
1.014MB
Format:
PDF
View/Open
Name:
xen12418_am.pdf
Size:
342.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.